Form 4: Sonoma Pharmaceuticals Executive Bruce Thornton Reports Stock Award and Disposal
SEC Form 4 Filing
Bruce Thornton, Executive Vice President of Sonoma Pharmaceuticals, reports the acquisition of 53,586 shares of common stock as part of an annual bonus and the disposal of 154,411 shares.
Summary
- On June 20, 2024, Bruce Thornton, Executive Vice President of Sonoma Pharmaceuticals, reported transactions involving the company's common stock.
- Thornton acquired 53,586 shares of common stock as part of the company's annual bonus compensation to executives.
- These shares were awarded as Restricted Stock Units and vested in full on the grant date.
- Thornton also disposed of 154,411 shares of common stock.
- Following these transactions, Thornton beneficially owns 154,411 shares of Sonoma Pharmaceuticals.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions by an executive. The sentiment is neutral as it simply reports facts without expressing any opinion or outlook.
Positives
- The award of Restricted Stock Units to executives as part of their annual bonus compensation aligns their interests with the company's performance.
Negatives
- The disposal of 154,411 shares by Thornton could be interpreted negatively by investors, although the reason for disposal is not specified.
Risks
- The document does not explicitly state the reason for the disposal of 154,411 shares, which could lead to speculation and uncertainty among investors.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders. Investors often monitor these filings to gain insights into management's sentiment and confidence in the company's prospects.
Stakeholder Impact
- The stock transactions reported in this filing may influence investor sentiment and potentially impact the company's stock price.
Key Dates
| Date | Description |
|---|---|
| 06/20/2024 | Date of stock acquisition and disposal transactions. |
| 06/21/2024 | Date of signature on the Form 4 filing. |
Keywords
Sonoma Pharmaceuticals, Bruce Thornton, stock, acquisition, disposal, Form 4, Restricted Stock Units, executive compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.